华纳药厂前三季净利同比增30.75% 研发投入超1亿元

Core Insights - Hunan Warner Pharmaceutical Co., Ltd. reported a revenue of 1.086 billion yuan for the first three quarters of 2025, a year-on-year increase of 1.55% [1] - The net profit attributable to shareholders reached 207 million yuan, reflecting a significant year-on-year growth of 30.75% [1] - Basic earnings per share increased to 1.58 yuan, up by 30.58% compared to the previous year [1] Financial Performance - Total assets of the company reached 2.781 billion yuan, marking a growth of 13.06% from the end of the previous year [1] - Revenue from formulation products was 805 million yuan, while raw materials and intermediates generated 262 million yuan [1] - Research and development investment for the first three quarters amounted to 106 million yuan, accounting for 9.75% of total revenue [2] Product Development - The company has developed 71 specialty chemical raw materials, with 53 of them having their registration status upgraded to "A" [1] - Warner Pharmaceutical is advancing multiple innovative drugs, including a traditional Chinese medicine entering phase III clinical trials and a new antidepressant in phase IIa trials [3] - The company aims to combine generic drug consolidation with innovative breakthroughs, focusing on both generic and innovative drug development strategies [3]